Susquehanna Fundamental Investments LLC Buys Shares of 15,400 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Susquehanna Fundamental Investments LLC purchased a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the second quarter, HoldingsChannel.com reports. The fund purchased 15,400 shares of the company’s stock, valued at approximately $465,000.

Other large investors have also bought and sold shares of the company. LSV Asset Management grew its stake in shares of Harmony Biosciences by 346.5% during the first quarter. LSV Asset Management now owns 335,146 shares of the company’s stock worth $11,254,000 after purchasing an additional 260,093 shares during the period. American Century Companies Inc. grew its position in shares of Harmony Biosciences by 53.7% during the 2nd quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock worth $20,562,000 after buying an additional 238,140 shares during the period. Renaissance Technologies LLC grew its position in shares of Harmony Biosciences by 56.7% during the 2nd quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock worth $17,975,000 after buying an additional 215,700 shares during the period. Capital Management Corp VA bought a new stake in shares of Harmony Biosciences in the 1st quarter valued at about $7,018,000. Finally, Marshall Wace LLP raised its holdings in Harmony Biosciences by 145.4% in the second quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock worth $9,220,000 after purchasing an additional 181,092 shares during the period. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HRMY has been the subject of a number of recent analyst reports. UBS Group began coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price objective for the company. Citigroup initiated coverage on Harmony Biosciences in a research note on Friday, June 21st. They set a “buy” rating and a $48.00 target price for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Wednesday. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $34.77 on Friday. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 15.05, a PEG ratio of 0.77 and a beta of 0.73. The firm has a fifty day simple moving average of $36.06 and a 200 day simple moving average of $32.69. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $40.60.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.24. The firm had revenue of $172.80 million during the quarter, compared to analysts’ expectations of $172.53 million. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The business’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.56 earnings per share. Research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.19 EPS for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.